Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Michael J BurkeRumen KostadinovRichard SpostoLia GoreShannon M KelleyCara RabikJane B TrepelMin-Jung LeeAkira YunoDeepa BhojwaniSima JehaBill H ChangMaria Luisa SulisMichelle L HermistonPaul GaynonVan HuynhAnupam VermaRebecca GardnerKenneth M HeymRobyn M DennisDavid S ZieglerTheodore W LaetschJavier E OesterheldSteven G DuboisJessica A PollardJulia Glade-BenderTodd M CooperJoel A KaplanMidhat S FarooqiByunggil YooErin M GuestAlan S WaynePatrick A BrownPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Despite encouraging response rates and pharmacodynamics, the combination of decitabine and vorinostat on this intensive chemotherapy backbone was determined not feasible in B-ALL due to the high incidence of significant infectious toxicities. This study is registered at http://www.clinicaltrials.gov as NCT01483690.